{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:06:18Z","timestamp":1791486378469,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute and recently acquired hepatitis C virus (HCV) infection clusters in men who have sex with men living with HIV and in people who inject drugs, where early cure benefits both the individual and transmission control. The best interferon-free dual direct-acting antiviral (DAA) regimen and treatment duration, including short courses, remain undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched to 1 July 2026 for studies of interferon-free dual-DAA therapy in acute or recently acquired HCV reporting SVR12. Each study was appraised as a single-arm case series, and proportions were pooled by random-intercept logistic regression. Pre-specified subgroups were regimen, treatment duration, study design, and HIV status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen studies (19 single-arm analysis units; 1078 treated patients) were included. Pooled SVR12 was 97.7% (95% CI 94.7\u201399.1; 1043\/1078; I\u00b2 = 30.4%). SVR12 rates increased with treatment duration, from 84.8% (74.1\u201391.6) at 4 weeks and 91.7% (86.2\u201395.1) at 6 weeks to 99.4% (97.5\u201399.9) at 8 weeks and 97.4% (91.7\u201399.2) at 12 weeks (between-subgroup\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas it did not differ by regimen (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.608), study design (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.764), or HIV status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.975). The pooled estimate was stable across sensitivity analyses (trials only, exclusion of the high-risk study, and leave-one-out).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dual-DAA therapy was associated with a high pooled SVR12 in acute and recently acquired HCV, with cure differing by treatment duration. These findings support early treatment and favour a course of at least eight weeks. Given the predominantly single-arm evidence and the partial confounding of regimen with duration, randomised duration-comparison trials are needed to confirm the optimal short-course strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03307-x","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:24:53Z","timestamp":1791375893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Nada","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy M. F.","family":"Elbarody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-5998","authenticated-orcid":false,"given":"Ahmed M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"3307_CR1","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. 2024."},{"key":"3307_CR2","first-page":"1","volume":"33","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. Who. 2022;33:1\u201312.","journal-title":"Who"},{"key":"3307_CR3","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"3307_CR4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"3307_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u201369.","journal-title":"N Engl J Med"},{"key":"3307_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","volume":"29","author":"H Hagan","year":"2015","unstructured":"Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS. 2015;29:2335\u201345.","journal-title":"AIDS"},{"key":"3307_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","volume":"136","author":"T an de Laar","year":"2009","unstructured":"an de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men. Gastroenterology. 2009;136:1609\u201317.","journal-title":"Gastroenterology"},{"key":"3307_CR8","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal. 2017;5:e1192\u2013207.","journal-title":"Lancet Glob Heal"},{"key":"3307_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","volume":"25","author":"JK Rockstroh","year":"2011","unstructured":"Rockstroh JK. Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference: The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Aids. 2011;25:399\u2013409.","journal-title":"Aids"},{"key":"3307_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat. 2006;13:34\u201341.","journal-title":"J Viral Hepat"},{"key":"3307_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/hep.26639","volume":"59","author":"J Grebely","year":"2014","unstructured":"Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109\u201320.","journal-title":"Hepatology"},{"key":"3307_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598\u2013609.","journal-title":"Hepatology"},{"key":"3307_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/cid\/cix1007","volume":"66","author":"A Boerekamps","year":"2018","unstructured":"Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, et al. Declining Hepatitis C Virus (HCV) incidence in Dutch Human Immunodeficiency Virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66:1360\u20135.","journal-title":"Clin Infect Dis"},{"key":"3307_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","author":"D Bhattacharya","year":"2023","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Heald J, Demisashi G, et al. Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases\u2013 Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad319.","journal-title":"Clin Infect Dis"},{"key":"3307_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","volume":"75","author":"GV Matthews","year":"2021","unstructured":"Matthews GV, Bhagani S, van der Valk M, Rockstroh J, Feld JJ, Rauch A, et al. Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;75:829\u201339.","journal-title":"J Hepatol"},{"key":"3307_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100867","volume":"5","author":"M Martinello","year":"2023","unstructured":"Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, et al. Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: the TARGET3D study. JHEP Rep. 2023;5:100867.","journal-title":"JHEP Rep"},{"key":"3307_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cid\/ciaf305","volume":"81","author":"AY Kim","year":"2026","unstructured":"Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, et al. Short Course Therapy With Glecaprevir\/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Clin Infect Dis. 2026;81:1083\u201390.","journal-title":"Clin Infect Dis"},{"key":"3307_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","volume":"66","author":"P Ingiliz","year":"2017","unstructured":"Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66:282\u20137.","journal-title":"J Hepatol"},{"key":"3307_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2015;62:683\u201394.","journal-title":"Clin Infect Dis"},{"key":"3307_CR20","doi-asserted-by":"publisher","first-page":"e0082","DOI":"10.1097\/HC9.0000000000000082","volume":"7","author":"L Manoharan","year":"2023","unstructured":"Manoharan L, Latham NH, Munari SC, Traeger MW, Menon V, Luhmann N, et al. Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: a systematic review and meta-analysis. Hepatol Commun. 2023;7:e0082.","journal-title":"Hepatol Commun"},{"key":"3307_CR21","volume":"2017","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;2017:CD012143.","journal-title":"Cochrane Database Syst Rev"},{"key":"3307_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2020. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"3307_CR23","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. J Am Med Assoc. 2000;283:2008\u201312.","journal-title":"J Am Med Assoc"},{"key":"3307_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R\u00fccker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10:476\u201383.","journal-title":"Res Synth Methods"},{"key":"3307_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13:147\u201353.","journal-title":"Int J Evid Based Healthc"},{"key":"3307_CR26","first-page":"60","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. Evid Based Med. 2018;23:60\u20133.","journal-title":"Evid Based Med"},{"key":"3307_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"3307_CR28","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046\u201367.","journal-title":"Stat Med"},{"key":"3307_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","volume":"316","author":"AE Stuck","year":"1998","unstructured":"Stuck AE, Rubenstein LZ, Wieland D, Vandenbroucke JP, Irwig L, Macaskill P, et al. Bias in meta-analysis detected by a simple, graphical. BMJ. 1998;316:469\u2013469.","journal-title":"BMJ"},{"key":"3307_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics"},{"key":"3307_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"3307_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-026-01381-w","author":"C Boesecke","year":"2026","unstructured":"Boesecke C, Workowski K, Gordon SC, Cave B, Marcinak J, Miller MG, et al. Glecaprevir\/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection. Infect Dis Ther. 2026. https:\/\/doi.org\/10.1007\/s40121-026-01381-w.","journal-title":"Infect Dis Ther"},{"key":"3307_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2025.11.009","volume":"84","author":"JM Llibre","year":"2025","unstructured":"Llibre JM, Boesecke C, Moon J, Lank PM, Miller MG, Fredrick LM, et al. A single-arm phase IIIb study of 8-week glecaprevir\/pibrentasvir treatment in adults with acute hepatitis C. J Hepatol. 2025;84:702\u201312.","journal-title":"J Hepatol"},{"key":"3307_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","volume":"2","author":"JK Rockstroh","year":"2017","unstructured":"Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir\u2013sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2:347\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3307_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/cid\/ciy913","volume":"69","author":"S Naggie","year":"2019","unstructured":"Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, et al. Ledipasvir\/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals. Clin Infect Dis. 2019;69:514\u201322.","journal-title":"Clin Infect Dis"},{"key":"3307_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640619835394","volume":"7","author":"D Chromy","year":"2019","unstructured":"Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United Eur Gastroenterol J. 2019;7:507\u201316.","journal-title":"United Eur Gastroenterol J"},{"key":"3307_CR37","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.3748\/wjg.v27.i37.6277","volume":"27","author":"MH Huang","year":"2021","unstructured":"Huang MH, Sun HY, Ho SY, Chang SY, Hsieh SM, Sheng WH, et al. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan. World J Gastroenterol. 2021;27:6277\u201389.","journal-title":"World J Gastroenterol"},{"key":"3307_CR38","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.eimce.2023.06.011","volume":"42","author":"L Mart\u00edn-Carbonero","year":"2024","unstructured":"Mart\u00edn-Carbonero L, Gutierrez \u00c1, Bisbal O, Vergas J, Gonz\u00e1lez-Baeza A, Rodr\u00edguez Mart\u00edn C, et al. Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. Enfermedades Infecc y Microbiol Clin (English ed). 2024;42:414\u20139.","journal-title":"Enfermedades Infecc y Microbiol Clin (English ed)"},{"key":"3307_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","volume":"17","author":"K Deterding","year":"2017","unstructured":"Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17:215\u201322.","journal-title":"Lancet Infect Dis"},{"key":"3307_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.31003","volume":"72","author":"M Martinello","year":"2020","unstructured":"Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, et al. Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72:7\u201318.","journal-title":"Hepatology"},{"key":"3307_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100650","volume":"5","author":"B Maasoumy","year":"2023","unstructured":"Maasoumy B, Ingiliz P, Spinner CD, Cordes C, Stellbrink H-J, Schulze zur Wiesch J, et al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: the HepNet acute HCV-V study. JHEP Reports. 2023;5:100650.","journal-title":"JHEP Reports"},{"key":"3307_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","volume":"4","author":"A Boerekamps","year":"2019","unstructured":"Boerekamps A, De Weggheleire A, van den Berk GE, Lauw FN, Claassen MAA, Posthouwer D, et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:269\u201377.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3307_CR43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/HEP.0000000000000923","volume":"81","author":"S Pol","year":"2025","unstructured":"Pol S, Thompson AJ, Collins M, Venier E, Cotte L, Laguno Centeno M, et al. Effectiveness and safety of glecaprevir\/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study. Hepatology. 2025;81:1006\u201318.","journal-title":"Hepatology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03307-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:02:34Z","timestamp":1791482554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03307-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3307"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03307-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review protocol was prepared a priori and submitted to the International Prospective Register of Systematic Reviews (PROSPERO). The registration number is CRD420261464486.","order":2,"name":"Ethics","label":"Registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"240"}}